Insilico releases AI-powered hardware platform, PandaOmics Box for on-premise drug discovery and personalized medicine research

(Press-News.org) The development of innovative medicines is an expensive, time-consuming and risky business. On average, it usually takes at least a decade and billions of dollars to bring a new drug from project initiation to approval. Identifying effective targets and conducting biological analysis is the first step in the process and remains a top priority in drug development.

To facilitate for maximum data privacy and data security, Insilico Medicine ("Insilico"), developed a hardware platform, PandaOmics Box, that does not require Internet access and allows for on-premise biological analytics, target identification, biomarker discovery, indication prioritization and advanced research in personalized medicine and drug discovery.  

The PandaOmics Box is a seamless integration of Insilico's proprietary generative biology AI software PandaOmics, extensive scientific database, and advanced hardware system with state-of-the-art computational power and chip-level confidential computing. Designed for on-premise deployment, the PandaOmics Box allows the product to operate efficiently in a completely offline mode, therefore provides a secure environment for privacy data analysis.

The solution is centered on PandaOmics, which encompasses more than 20 predictive models and generative biology models, and includes a full spectrum of transcriptomics, genomics, epigenomics, proteomics, single cell data and compound information generated by the scientific community. It supports professional target ranking, analysis and filters, empowering more efficient and convenient research for potential targets and biomarkers.

It is further enhanced by a powerful local Large Language Model (LLM), marking it as a truly all-encompassing tool for research. Its array of additional superior features include: ChatPandaGPT,  which allows researchers to engage with Insilico Medicine's knowledge graph database via intuitive, natural language conversations; Gene-Disease Report function, which streamlines the user's research efforts by automatically generating comprehensive reports that provide a comprehensive analysis of a specific research area, and Paper Drafting Tool, which is designed to assist researchers in creating well-structured draft papers, making the transition from research to publication smoother.

Additionally, the system is equipped with OpenAPI framework, and allows Bioinformatics access to PandaOmics' extensive database and advanced AI algorithms. This feature provides researchers the flexibility to develop their own custom analyses, enabling them to create innovative methods that blend with their proprietary data for deeper insights.

“Personal medical and biological data must be secure and there is nothing more secure than a device that does not connect to the Internet, does not even have WiFi and even internally uses on-chip confidential computing but can perform many research functions that previously required access to the Internet or were not possible at all. While many hospitals, institutes, and biotech companies hold large amounts of data of their own, they are concerned that putting data in the cloud will lose its value or violate data privacy regulations. We want to help them unlock the value of that data, generate unprecedented value for the patients, and perform cutting-edge research.” said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. “We offer on-premise PandaOmics Box that supports scientists to conduct cutting-edge tasks such as target identification, biomarker discovery, and indication prioritization in one hardware with no internet connection. Also, the array of exceptional features supported by LLM and open API further enhance the research experience.”

Overall, PandaOmics Box, the innovative platform, is tailor-made to transform the research landscape, empowering researchers to excel in target identification, biomarker discovery and indication prioritization. Leveraging Insilico Medicine's exceptional AI capabilities, researchers are equipped with a powerful ally in their quest for groundbreaking advancements in target identification and drug development. 

Insilico Medicine is a pioneer in using generative AI for drug discovery and development. The Company first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016. Then, Insilico developed and validated multiple approaches and features for its generative adversarial network (GAN)-based AI platform and integrated those algorithms into the commercially available Pharma.AI platform, which includes generative biology, chemistry, and medicine.

 

Since 2021, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 promising therapeutic assets and has advanced seven molecules to the clinical stage. In March 2024, the Company published a paper in Nature Biotechnology that discloses the raw experimental data and the preclinical and clinical evaluation of its lead drug – a potentially first-in-class TNIK inhibitor for the treatment of idiopathic pulmonary fibrosis discovered and designed using generative AI currently in Phase II trials with patients. 

 

About Insilico Medicine

Insilico Medicine, a global clinical-stage biotechnology company powered by generative AI, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and generating novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com

END